These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Management of rosiglitazone-induced edema: two case reports and a review of the literature. Wang F; Aleksunes LM; Reagan LA; Vergara CM Diabetes Technol Ther; 2002; 4(4):505-14. PubMed ID: 12396745 [TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Mudaliar S; Chang AR; Henry RR Endocr Pract; 2003; 9(5):406-16. PubMed ID: 14583425 [TBL] [Abstract][Full Text] [Related]
4. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Kermani A; Garg A Mayo Clin Proc; 2003 Sep; 78(9):1088-91. PubMed ID: 12962163 [TBL] [Abstract][Full Text] [Related]
5. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Bonkovsky HL; Azar R; Bird S; Szabo G; Banner B Dig Dis Sci; 2002 Jul; 47(7):1632-7. PubMed ID: 12141828 [TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Cheng-Lai A; Levine A Heart Dis; 2000; 2(4):326-33. PubMed ID: 11728276 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of thiazolidinedione derivative drugs for safety]. Kobayashi M; Iwata M Nihon Rinsho; 2001 Nov; 59(11):2228-32. PubMed ID: 11712412 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Lebovitz HE; Kreider M; Freed MI Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674 [TBL] [Abstract][Full Text] [Related]
11. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. Tang WH; Francis GS; Hoogwerf BJ; Young JB J Am Coll Cardiol; 2003 Apr; 41(8):1394-8. PubMed ID: 12706937 [TBL] [Abstract][Full Text] [Related]
12. Second-generation thiazolidinediones and hepatotoxicity. Marcy TR; Britton ML; Blevins SM Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041 [TBL] [Abstract][Full Text] [Related]
13. [The development of thiazolidinedione drugs as anti-diabetic agents]. Kuzuya T Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559 [TBL] [Abstract][Full Text] [Related]
14. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico. Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639 [TBL] [Abstract][Full Text] [Related]
15. Hepatic failure in a patient taking rosiglitazone. Forman LM; Simmons DA; Diamond RH Ann Intern Med; 2000 Jan; 132(2):118-21. PubMed ID: 10644272 [TBL] [Abstract][Full Text] [Related]
16. A review of rosiglitazone in type 2 diabetes mellitus. Werner AL; Travaglini MT Pharmacotherapy; 2001 Sep; 21(9):1082-99. PubMed ID: 11560198 [TBL] [Abstract][Full Text] [Related]
17. Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. Kahara T; Takamura T; Misaki T; Sakurai M; Takeshita Y; Shimizu A; Kaneko S Endocr J; 2005 Jun; 52(3):373-6. PubMed ID: 16006733 [TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone-induced anasarca without heart failure: capillary leakage? Dagdelen S; Kurt M; Aydin K; Bayraktar M Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557 [TBL] [Abstract][Full Text] [Related]
19. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug]. Toyota T Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410 [TBL] [Abstract][Full Text] [Related]